{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T21:56:35Z","timestamp":1790546195800,"version":"4.1.0"},"reference-count":37,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,6,19]],"date-time":"2024-06-19T00:00:00Z","timestamp":1718755200000},"content-version":"vor","delay-in-days":18,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000038","name":"U.S. Food and Drug Administration","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000038","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Heliyon"],"published-print":{"date-parts":[[2024,6]]},"DOI":"10.1016\/j.heliyon.2024.e33306","type":"journal-article","created":{"date-parts":[[2024,6,19]],"date-time":"2024-06-19T20:05:41Z","timestamp":1718827541000},"page":"e33306","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Safety assessment of dapagliflozin: Real-world adverse event analysis based on the FAERS database from 2012 to 2023"],"prefix":"10.1016","volume":"10","author":[{"given":"Zhengxi","family":"Zhou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaotian","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.heliyon.2024.e33306_bib1","doi-asserted-by":"crossref","DOI":"10.1530\/EC-23-0005","article-title":"SGLT2 inhibitors for patients with type 2 diabetes and CKD: a narrative review","volume":"12","author":"Thomas","year":"2023","journal-title":"Endocr Connect"},{"key":"10.1016\/j.heliyon.2024.e33306_bib2","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1007\/s40265-019-01148-3","article-title":"Dapagliflozin: a review in type 2 diabetes","volume":"79","author":"Dhillon","year":"2019","journal-title":"Drugs"},{"key":"10.1016\/j.heliyon.2024.e33306_bib3","doi-asserted-by":"crossref","first-page":"2352","DOI":"10.1681\/ASN.2021020167","article-title":"Effects of dapagliflozin in stage 4 chronic kidney disease","volume":"32","author":"Chertow","year":"2021","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.heliyon.2024.e33306_bib4","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1007\/s12325-021-01994-2","article-title":"Chronic kidney disease and SGLT2 inhibitors: a review of the evolving treatment landscape","volume":"39","author":"Mende","year":"2022","journal-title":"Adv. Ther."},{"key":"10.1016\/j.heliyon.2024.e33306_bib5","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1016\/j.jacc.2022.07.021","article-title":"Dapagliflozin in patients recently hospitalized with heart failure and mildly reduced or preserved ejection fraction","volume":"80","author":"Cunningham","year":"2022","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.heliyon.2024.e33306_bib6","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1002\/ehf2.12555","article-title":"Highlights in heart failure","volume":"6","author":"Tomasoni","year":"2019","journal-title":"ESC Heart Fail"},{"key":"10.1016\/j.heliyon.2024.e33306_bib7","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1161\/CIRCULATIONAHA.120.050391","article-title":"Efficacy of dapagliflozin on renal function and outcomes in patients with heart failure with reduced ejection fraction: results of DAPA-HF","volume":"143","author":"Jhund","year":"2021","journal-title":"Circulation"},{"key":"10.1016\/j.heliyon.2024.e33306_bib8","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1161\/HYPERTENSIONAHA.123.20598","article-title":"Functional and clinical importance of SGLT2-inhibitors in frailty: from the kidney to the heart","volume":"80","author":"Santulli","year":"2023","journal-title":"Hypertension"},{"key":"10.1016\/j.heliyon.2024.e33306_bib9","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1056\/NEJMoa1812389","article-title":"Dapagliflozin and cardiovascular outcomes in type 2 diabetes","volume":"380","author":"Wiviott","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.heliyon.2024.e33306_bib10","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.kint.2022.06.008","article-title":"KDIGO 2022 clinical practice guideline for diabetes management in chronic kidney disease","volume":"102","year":"2022","journal-title":"Kidney Int."},{"key":"10.1016\/j.heliyon.2024.e33306_bib11","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1007\/s00592-022-02015-6","article-title":"SGLT-2 inhibitors and euglycemic diabetic ketoacidosis\/diabetic ketoacidosis in FAERS: a pharmacovigilance assessment","volume":"60","author":"He","year":"2023","journal-title":"Acta Diabetol."},{"key":"10.1016\/j.heliyon.2024.e33306_bib12","first-page":"1","article-title":"Urinary tract infections and genital mycotic infections associated with SGLT-2 inhibitors: an analysis of the FDA Adverse Event Reporting System","author":"Yang","year":"2023","journal-title":"Expet Opin. Drug Saf."},{"key":"10.1016\/j.heliyon.2024.e33306_bib13","doi-asserted-by":"crossref","DOI":"10.1016\/j.cpcardiol.2024.102664","article-title":"Pharmacovigilance study for SGLT 2 inhibitors- Safety review of real-world data & randomized clinical trials","author":"Bhanushali","year":"2024","journal-title":"Curr. Probl. Cardiol."},{"key":"10.1016\/j.heliyon.2024.e33306_bib14","doi-asserted-by":"crossref","DOI":"10.3389\/fpsyt.2022.917351","article-title":"Comparative safety signal assessment of hospitalization associated with the use of atypical antipsychotics","volume":"13","author":"Yunusa","year":"2022","journal-title":"Front. Psychiatr."},{"key":"10.1016\/j.heliyon.2024.e33306_bib15","doi-asserted-by":"crossref","DOI":"10.3389\/fdsfr.2023.1323057","article-title":"Conducting and interpreting disproportionality analyses derived from spontaneous reporting systems","volume":"3","author":"Cutroneo","year":"2024","journal-title":"Front Drug Saf Regul"},{"key":"10.1016\/j.heliyon.2024.e33306_bib16","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.ejim.2019.03.014","article-title":"Euglycemic diabetic ketoacidosis","volume":"63","author":"Barski","year":"2019","journal-title":"Eur. J. Intern. Med."},{"key":"10.1016\/j.heliyon.2024.e33306_bib17","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.2337\/dc15-0843","article-title":"Euglycemic diabetic ketoacidosis: a potential complication of treatment with sodium-glucose cotransporter 2 inhibition","volume":"38","author":"Peters","year":"2015","journal-title":"Diabetes Care"},{"key":"10.1016\/j.heliyon.2024.e33306_bib18","article-title":"Ketoacidosis with euglycemia in a patient with type 2 diabetes mellitus taking dapagliflozin: a case report","volume":"98","author":"Yeo","year":"2019","journal-title":"Medicine (Baltim.)"},{"key":"10.1016\/j.heliyon.2024.e33306_bib19","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1111\/jdi.12401","article-title":"Euglycemic diabetic ketoacidosis induced by SGLT2 inhibitors: possible mechanism and contributing factors","volume":"7","author":"Ogawa","year":"2016","journal-title":"J Diabetes Investig"},{"key":"10.1016\/j.heliyon.2024.e33306_bib20","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.2337\/dc15-1380","article-title":"Euglycemic diabetic ketoacidosis: a predictable, detectable, and preventable safety concern with SGLT2 inhibitors","volume":"38","author":"Rosenstock","year":"2015","journal-title":"Diabetes Care"},{"key":"10.1016\/j.heliyon.2024.e33306_bib21","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1016\/S2213-8587(16)30267-4","volume":"4","author":"Fr\u00edas","year":"2016","journal-title":"Lancet Diabetes Endocrinol."},{"key":"10.1016\/j.heliyon.2024.e33306_bib22","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1111\/dom.14261","article-title":"Effectiveness and safety of sodium-glucose co-transporter-2 inhibitors compared with dipeptidyl peptidase-4 inhibitors in older adults with type 2 diabetes: a nationwide population-based study","volume":"23","author":"Han","year":"2021","journal-title":"Diabetes Obes. Metabol."},{"key":"10.1016\/j.heliyon.2024.e33306_bib23","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2018-022577","article-title":"Comparative safety of the sodium glucose co-transporter 2 (SGLT2) inhibitors: a systematic review and meta-analysis","volume":"9","author":"Donnan","year":"2019","journal-title":"BMJ Open"},{"key":"10.1016\/j.heliyon.2024.e33306_bib24","doi-asserted-by":"crossref","first-page":"861","DOI":"10.3390\/healthcare11060861","article-title":"Prevalence and associated risk factors of urinary tract infection among diabetic patients: a cross-sectional study","volume":"11","author":"Ahmed","year":"2023","journal-title":"Healthcare (Basel)"},{"key":"10.1016\/j.heliyon.2024.e33306_bib25","doi-asserted-by":"crossref","first-page":"861","DOI":"10.3390\/healthcare11060861","article-title":"Prevalence and associated risk factors of urinary tract infection among diabetic patients: a cross-sectional study","volume":"11","author":"Ahmed","year":"2023","journal-title":"Healthcare (Basel)"},{"key":"10.1016\/j.heliyon.2024.e33306_bib26","doi-asserted-by":"crossref","first-page":"F227","DOI":"10.1152\/ajprenal.00689.2014","article-title":"Acute SGLT inhibition normalizes O2 tension in the renal cortex but causes hypoxia in the renal medulla in anaesthetized control and diabetic rats","volume":"309","author":"O'Neill","year":"2015","journal-title":"Am. J. Physiol. Ren. Physiol."},{"key":"10.1016\/j.heliyon.2024.e33306_bib27","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1111\/dom.12127","article-title":"Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes","volume":"15","author":"Lambers Heerspink","year":"2013","journal-title":"Diabetes Obes. Metabol."},{"key":"10.1016\/j.heliyon.2024.e33306_bib28","doi-asserted-by":"crossref","first-page":"176","DOI":"10.14740\/jocmr2849w","article-title":"Increased hematocrit during sodium-glucose cotransporter-2 inhibitor therapy","volume":"9","author":"Heyman","year":"2017","journal-title":"J. Clin. Med. Res."},{"key":"10.1016\/j.heliyon.2024.e33306_bib29","doi-asserted-by":"crossref","first-page":"262","DOI":"10.7326\/0003-4819-159-4-201308200-00007","article-title":"Sodium-glucose cotransporter 2 inhibitors for type 2 diabetes: a systematic review and meta-analysis","volume":"159","author":"Vasilakou","year":"2013","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.heliyon.2024.e33306_bib30","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1016\/j.numecd.2017.10.011","article-title":"Acute renal failure with sodium-glucose-cotransporter-2 inhibitors: analysis of the FDA adverse event report system database","volume":"27","author":"Perlman","year":"2017","journal-title":"Nutr. Metabol. Cardiovasc. Dis."},{"key":"10.1016\/j.heliyon.2024.e33306_bib31","doi-asserted-by":"crossref","first-page":"827","DOI":"10.3390\/nu9080827","article-title":"Dietary flavonoid intake is inversely associated with cardiovascular disease risk as assessed by body mass index and waist circumference among adults in the United States","volume":"9","author":"Sebastian","year":"2017","journal-title":"Nutrients"},{"key":"10.1016\/j.heliyon.2024.e33306_bib32","doi-asserted-by":"crossref","first-page":"3159","DOI":"10.1080\/10408398.2017.1353480","article-title":"Flavonoids in fruits and vegetables after thermal and nonthermal processing: a review","volume":"58","author":"Ahmed","year":"2018","journal-title":"Crit. Rev. Food Sci. Nutr."},{"key":"10.1016\/j.heliyon.2024.e33306_bib33","article-title":"Analysis of acute pancreatitis associated with SGLT-2 inhibitors and predictive factors of the death risk: based on food and drug administration adverse event report system database","volume":"13","author":"Zhang","year":"2022","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.heliyon.2024.e33306_bib34","article-title":"Analysis of acute pancreatitis associated with SGLT-2 inhibitors and predictive factors of the death risk: based on food and drug administration adverse event report system database","volume":"13","author":"Zhang","year":"2022","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.heliyon.2024.e33306_bib35","doi-asserted-by":"crossref","first-page":"405","DOI":"10.4291\/wjgp.v5.i4.405","article-title":"Contemporary review of drug-induced pancreatitis: a different perspective","volume":"5","author":"Hung","year":"2014","journal-title":"World J. Gastrointest. Pathophysiol."},{"key":"10.1016\/j.heliyon.2024.e33306_bib36","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1016\/j.cgh.2006.11.023","article-title":"Drug-induced acute pancreatitis: an evidence-based review","volume":"5","author":"Badalov","year":"2007","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"10.1016\/j.heliyon.2024.e33306_bib37","article-title":"Dapagliflozin-induced acute pancreatitis: a case report and review of literature","volume":"2020","author":"Sujanani","year":"2020","journal-title":"Case Rep Endocrinol"}],"container-title":["Heliyon"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S240584402409337X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S240584402409337X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T21:03:25Z","timestamp":1790543005000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S240584402409337X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6]]},"references-count":37,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2024,6]]}},"alternative-id":["S240584402409337X"],"URL":"https:\/\/doi.org\/10.1016\/j.heliyon.2024.e33306","relation":{},"ISSN":["2405-8440"],"issn-type":[{"value":"2405-8440","type":"print"}],"subject":[],"published":{"date-parts":[[2024,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safety assessment of dapagliflozin: Real-world adverse event analysis based on the FAERS database from 2012 to 2023","name":"articletitle","label":"Article Title"},{"value":"Heliyon","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.heliyon.2024.e33306","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"e33306"}}